Our findings unveiled a notable negative correlation between FCN1 expression and the stemness score in AML, indicating that tumor cells with reduced FCN1 expression harbor heightened stemness and may develop resistance to treatment. The gene discussed is FCN1; the disease is acute myeloid leukemia.